Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2026-02-18 @ 2:48 AM
Study NCT ID:
NCT04168502
Status:
RECRUITING
Last Update Posted:
2024-11-08
First Post:
2019-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
AML1819
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None